Malcolm Anderson,
David M Andrews,
Andy J Barker, Claire A Brassington,
Jason Breed,
Kate F Byth,
Janet D Culshaw,
M Raymond V Finlay,
Eric Fisher,
Helen H J McMiken, [......],
Ian A Nash,
Nicholas J Newcombe,
Sandra E Oakes,
Richard A Pauptit,
Andrew Roberts,
Judith J Stanway,
Andrew P Thomas,
Julie A Tucker,
Mike Walker,
Hazel M Weir
[show abstract]
[hide abstract]
ABSTRACT: An imidazole series of cyclin-dependent kinase (CDK) inhibitors has been developed. Protein inhibitor structure determination has provided an understanding of the emerging structure activity trends for the imidazole series. The introduction of a methyl sulfone at the aniline terminus led to a more orally bioavailable CDK inhibitor that was progressed into clinical development.
Bioorganic & medicinal chemistry letters 10/2008; 18(20):5487-92. · 2.65 Impact Factor
